Retrospective Cohort Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jul 21, 2019; 25(27): 3607-3618
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3607
Table 2 Stratified analysis comparing transarterial chemoembolization treatment in barcelona clinic liver cancer stage B
VariableBCLC stage B overall (n = 135)BCLC stage B with TACE (n = 77)BCLC stage B without TACE (n = 58)P value
Age, yr (± SD)65 ± 1065 ± 865 ± 110.86
Male gender, n (%)111 (82.2)68 (88.3)43 (74.1)0.03
Non-cirrhotic liver, n (%)23 (17.0)7 (9.1)16 (27.6)0.006
Etiology, n (%)0.11
HCV42 (31.1)25 (32.5)17 (29.3)
HBV8 (5.9)5 (6.5)3 (5.2)
Alcohol29 (21.5)21 (27.3)8 (13.8)
Etiology, nNASH14 (10.4)6 (7.8)8 (13.8)
Etiology, nOthers42 (31.1)20 (25.9)22 (37.9)
Child Pugh A/B, n (%)88 (65.2)/47 (34.8)48 (62.3)/29 (37.7)40 (69.0)/18 (31.0)0.42
CSPH1, n (%)67 (49.6)45 (58.4)22 (37.9)0.018
Median nº HCC nodules (IQR)2 (2-3)2 (1-3)2 (1-4)0.39
Median largest HCC diameter, mm, (IQR)65 (43-100)60 (43-88)69.5 (45-114.5)0.11
Bilobar involvement, n (%)53 (39.3)30 (39.0)23 (39.7)0.72
Diffuse HCC pattern, n (%)5 (3.7)2 (2.6)3 (5.2)0.72
Median AFP, ng/mL (IQR)26.7 (4.7-248.5)27.5 (5.1-202.85)24.4 (4.3-285)0.91
AFP > 200 ng/mL, n (%)36 (27.3)19 (25.0)17 (30.4)0.49
AFP > 400 ng/mL, n (%)30 (22.7)17 (22.4)13 (23.2)0.91
AFP > 1000 ng/mL, n (%)18 (13.6)11 (14.5)7 (12.5)0.74
Vascular invasion, n (%)-
Extrahepatic disease, n (%)-
1Clinically significant portal hypertension defined as presence of at least one of the following: Ascites, gastro-aesophagueal varices or hepatic encephalopathy. AFP: Alpha-feto protein; TACE: Transarterial chemoembolization; BCLC: Barcelona clinic liver cancer.